Study prodromal Parkinson signs in GBA1 mutation carriers
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are willing to participate in the study.
- You do not currently have Parkinson’s disease.
- You do not have dementia (memory/thinking problems severe enough to be diagnosed as dementia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a protein called alpha-synuclein spreads in Parkinson's disease by checking blood and brain scans. It aims to understand why some people develop Parkinson's and to find clues that could lead to better treatments.
This study tests whether an experimental drug called prasinezumab can help prevent memory and thinking problems in people with Parkinson's disease who carry a specific GBA gene change. It aims to slow down cognitive decline and improve quality of life.
This trial tests a new gene therapy for Parkinson's disease in people who have a specific genetic change (GBA1 mutation) that may be causing their symptoms. The treatment aims to fix the root cause by delivering a corrected gene to the brain, which might help improve motor symptoms and reduce 'off' time.
This registry collects information about people with Parkinson’s who have specific changes in the GBA gene. The goal is to better understand how these gene changes affect Parkinson’s and support future research.
This study looks at whether people with Parkinson's disease who have a specific gene change (GBA mutation) have a higher chance of developing cancer. It will help doctors understand the link between these conditions.
This study aims to understand genetic factors in lysosomal storage disorders—rare conditions where the body cannot break down certain substances. Researchers will collect information from patients with these disorders, their family members, and healthy volunteers to learn how these diseases develop and affect people over time.
Hear when a new Gaucher Disease Type 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.